IL6 and COVID-19: Furthermore, an uncontrolled, exploratory study showed that for patients with COVID-19, IFN-α2b therapy appeared to shorten the duration of viral shedding, accelerating viral clearance from the respiratory tract and reducing the concentration of IL-6 [14].